Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.
Based on the PubMed abstract, this review explains how sample selection, experimental balance, outlier handling, transformation, and statistical methods affect anti-drug antibody assay cut points. It addresses screening, confirmation, titers, drug tolerance, and reassessment using clinical baseline samples. This is a practical review of validation decisions, not a new clinical efficacy study.
Based on the PubMed abstract, a Bioanalysis review examines switchable-hydrophilicity solvents and bio-derived deep eutectic solvents for sample preparation. It discusses extraction performance, matrix effects, reproducibility, and environmental trade-offs, with future emphasis on miniaturization and automation. The review evaluates methodological opportunities rather than validating a specific assay for regulated clinical sample analysis.
Labcorp posted a CBF 2026 conference-poster summary describing a direct assay format for neutralizing anti-drug antibodies. The approach is intended to address limitations of competitive assays when drug–target affinity is weak or signals are unstable. The public summary presents the assay concept, rather than quantitative validation results or a peer-reviewed clinical study.
Labcorp's CBF 2026 poster summary describes a unified serum free-IgE assay supporting comparison of two IgE-targeting drug candidates, including a marketed comparator. The team evaluated assay conditions that can disturb drug–IgE equilibrium and reports establishing a fit-for-purpose method. The public summary does not identify the therapies or provide numerical validation metrics; it is a conference report.
Wave's quarterly update describes planning for a registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence.
BioAgilytix announced a new 360biolabs laboratory in Sydney's Macquarie Park district. The company describes support for time-sensitive clinical samples, PBMC isolation, flow cytometry, and sample storage. It says shared procedures and quality systems support assay transfer across its laboratory network. These are company-reported capabilities.
This review surveys improvements in proteomics sample preparation, instrumentation, data acquisition, and analysis. It connects single-cell and spatial profiling with protein interactions, modifications, and biomarker discovery in body fluids. Clinical implementation is discussed as an opportunity with remaining challenges, rather than proof that every discovery assay is ready for diagnostic use.
Continue your research
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
